Option chain shows key data for Daito Trust Construction's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Daito Trust Construction.

Daito Trust Construction (OTC:DIFTY) Stock, Option Chain

Daito Trust Construction Co Ltd engages in the design and construction of apartments, condominiums, rental office buildings, factories, and warehouses. Additional activities include tenant recruiting, building maintenance, and contracting arrangements. A Lease Management Trust System sits at the center of Daito's operations. Under this system, business is divided between the construction business and the real estate business. The company plans and proposes building rental businesses to landowners, and then designs and constructs the contracted rental buildings. Daito also recruits tenants for its constructed rental buildings and provides property management and operation services for the buildings.

News

Intraday Update

Markets

Movers

Trading Ideas

AAEEF

AAVMY

ABEV

ABGSF

ABMD

ABTX

ACCFF

ACCYY

ACHV

ACNB

ACRFF

ACRGF

ACSAY

ACST

ACTG

ADMA

ADTN

ADVZF

AERI

AFLYY

AGCO

AGEEF

AGESY

AGLXY

AHFD

AHKSY

AHOTF

AICAF

AINV

AIPUY

AIRG

AIRYY

AISSF

AKO-A

AKZOY

ALDX

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

ALEX

Allianz Ag Muenchen Namen-Akt Vinkuliert Shares

ALIZF

ALLY

ALOT

ALSN

ALTM

ALXEF

ALXN

AMCR

AMHPF

AMKBF

AMKBY

AMNB

AMPH

AMRN

AMSLF

ANAT

ANGO

ANIP

Australia and New Zealand Banking Group Limited

ANZBY

ANZFF

APELY

APEX

APHA

APTS

ARCB

ARCC

ARGGY

ARGO

ARLP

ARNA

ARNGF

AROC

ARREF

ARRRF

Stocks That Hit 52-Week Lows On Friday

ABIO

ABVC

ACIW

ACOR

ACRX

ADHC

ADMP

AEGOF

AFRAF

AIBGY

AKRX

ALMFF

AMADY

AMCX

AMNP

AMRH

AMRQQ

AMTX

ANCN

ANZLY

APLE

AQARF

ARCH

ARTL

ASNA

ASTVF

ATRA

ATRI

ATROB

ATSG

ATUSF

AUTL

Stocks That Hit 52-Week Lows On Thursday

ABCE

AMGDF

APRN

ASIX

ATRO

AYTU

BCDRF

BFCH

BICEY

BNPUF

BOIVF

BORR

CDEV

CDZI

CESTY

CHRW

CJPRY

CJREF

CLVLF

CNDT

COWI

CPMD

CRWG

CSOD

China Shenhua Energy Unsponsored representing A shares

CSUAY

CTHR

CULP

CUYTF

CWSFF

CWVWF

CXXIF

DGRLY

DIFTY

DIIBF

DLTH

DMRC

DNTUY

DSSI

DXBRF

EJPRY

EKTAF

EKTAY

AB Electrolux Class B American Depositary Receipts

ELUXY

ELVT

ENLC

EZPW

FANG

FARE

FLMN

FLOOF

FLWPF

GGTTF

GLYE

GOGL

GPDNF

Stocks That Hit 52-Week Lows On Tuesday

DAITO TR CONSTR SP/ADR by Daito Trust Construction Co.

Daito Trust Construction Co Ltd

AIMD

Nasdaq Grants Ainos 180-Day Extension To Regain Compliance

<p><a href="https://www.consumerfinance.gov/about-us/newsroom/cfpb-orders-equifax-to-pay-15-million-for-improper-investigations-of-credit-reporting-errors/" title="https://www.consumerfinance.gov/about-us/newsroom/cfpb-orders-equifax-to-pay-15-million-for-improper-investigations-of-credit-reporting-errors/">https://www.consumerfinance.gov/about-us/newsroom/cfpb-orders-equifax-to-pay-15-million-for-improper-investigations-of-credit-reporting-errors/</a></p>


Legal

CFPB Orders Equifax To Pay $15M For Improper Investigations Of Credit Reporting Errors

BUSE

Federal Reserve Approves First Busey Acquisition Of CrossFirst Bankshares

Management

CUBE

Cubesmart Chief Operating Officer Joel Keaton Will Retire Effective April 30, 2025

<p>7 analysts have expressed a variety of opinions on Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $20.14, along with a high estimate of $27.00 and a low estimate of $17.00. Marking an increase of 38.9%, the current average surpasses the previous average price target of $14.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737122453_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of Viant Technology among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Nat Schindler</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>Maria Ripps</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$17.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Jason Kreyer</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Maria Ripps</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Viant Technology. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Viant Technology compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Viant Technology's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Viant Technology's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DSP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Viant Technology analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Viant Technology</h2>
<p>Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.</p>
<h3>Key Indicators: Viant Technology's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Viant Technology's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>34.13%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Viant Technology's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>1.89%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Viant Technology's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.46%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.36%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Viant Technology's debt-to-equity ratio is below the industry average at <strong>0.45</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

A Glimpse Into The Expert Outlook On Viant Technology Through 7 Analysts

<p>Throughout the last three months, 4 analysts have evaluated Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $26.0, along with a high estimate of $28.00 and a low estimate of $25.00. Observing a downward trend, the current average is 8.77% lower than the prior average price target of $28.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737122445_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Avantor. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Avantor. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Avantor compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Avantor's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>To gain a panoramic view of Avantor's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AVTR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Avantor analyst ratings.</strong></a></p>
<h2>Delving into Avantor's Background</h2>
<p>Avantor Inc provider of products and services to customers in the biopharma, healthcare, education &amp; government, and advanced technologies &amp; applied materials industries. The company has three geographic segments: the Americas, Europe, and AMEA. The company's product group consists of Equipment &amp; instrumentation, Services &amp; specialty procurement, Proprietary materials &amp; consumables, and Third-party materials &amp; consumables. Materials &amp; consumables include high-purity chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, and education and microbiology and clinical trial kits, peristaltic pumps and fluid handling tips.</p>
<h3>Avantor: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Challenges:</strong> Avantor's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately <strong>-0.34%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>3.37%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Avantor's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.05%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.45%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.89</strong>, Avantor adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AVTR

What Analysts Are Saying About Avantor Stock

<p>Life Time Group Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTH#NYSE">LTH</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $28.7, with a high estimate of $31.50 and a low estimate of $26.00. This current average reflects an increase of 5.83% from the previous average price target of $27.12. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737122436_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Life Time Group Hldgs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Hirsh</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Owen Rickert</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$31.50</td>
<td>$29.00</td>
</tr>
<tr>
<td>Daniel Politzer</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>JESALYN Wong</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>Owen Rickert</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$29.00</td>
<td>$28.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Life Time Group Hldgs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Life Time Group Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Life Time Group Hldgs's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Life Time Group Hldgs's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LTH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Life Time Group Hldgs analyst ratings.</strong></a></p>
<h2>Discovering Life Time Group Hldgs: A Closer Look</h2>
<p>Life Time Group Holdings Inc is a lifestyle brand offering health, fitness and wellness experiences to a community. It is engaged in designing, building, and operating distinctive and large, multi-use sports and athletic, professional fitness, family recreation and spa centers in a resort-like environment, principally in residential locations of metropolitan areas in the United States and Canada.</p>
<h3>Life Time Group Hldgs: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Life Time Group Hldgs displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>18.47%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Life Time Group Hldgs's net margin excels beyond industry benchmarks, reaching <strong>5.97%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>1.68%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.58%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Life Time Group Hldgs's debt-to-equity ratio is below the industry average at <strong>1.61</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 5 Analyst Projections For Life Time Group Hldgs

<p>Across the recent three months, 7 analysts have shared their insights on Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $7.14, a high estimate of $10.00, and a low estimate of $5.00. This current average represents a 2.06% decrease from the previous average price target of $7.29. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737122426_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of Absci among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Absci. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Absci compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Absci's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Absci's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ABSI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Absci analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know Absci Better</h2>
<p>Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.</p>
<h3>Unraveling the Financial Story of Absci</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Absci's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>128.63%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Absci's net margin excels beyond industry benchmarks, reaching <strong>-1610.7%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Absci's ROE excels beyond industry benchmarks, reaching <strong>-12.96%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Absci's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-11.17%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Absci's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.06</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ABSI

Absci Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)

<p>Needham  analyst Kyle Peterson   reiterates Cardlytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) from Hold to Hold.</p>


Reiteration

CDLX

Needham Reiterates Hold on Cardlyticsto Hold

Comments

Daito Trust Construction

Daito Trust Construction (DIFTY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga